Cytokeratin 8 as a Novel Therapeutic Target in Type 2 Diabetes Mellitus: Suppression of Hepatic Glycogen Synthesis via IRS1/PI3K/Akt/GSK3βSignaling
These findings position CK8 as a promising therapeutic target for T2DM, with CK8 inhibition offering a novel strategy to improve hepatic insulin resistance and glycogen storage without requiring β-cell stimulation.
Authors
- Zhidong Wang (ORCID: https://orcid.org/0000-0003-0594-1638)
- Jin Sun (ORCID: https://orcid.org/0000-0003-4332-2870)
- Mingzhu Sun (ORCID: https://orcid.org/0000-0002-1825-6093)
- Xiuli Li
Institutions
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Current Drug Targets
- Published
- 2025-10-01
- DOI
- https://doi.org/10.2174/0113894501394500250903095958
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00